HilleVax, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel vaccines. The company is headquartered in Boston, Massachusetts and currently employs 14 full-time employees. The company went IPO on 2022-04-29. The firm's programs, HIL-214 and HIL-216, are virus-like particle (VLP) based vaccine candidates in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. HIL-214 consists of VLPs which are designed to mimic the structure of norovirus and are co-formulated with an alum adjuvant to enhance immunogenicity and stability of the VLPs in solution. HIL-214 is administered intramuscularly via prefilled syringes and has demonstrated stability at standard refrigeration temperatures of four degrees Celsius for 24 months. The firm has in-licensed HIL-216 from Chengdu Kanghua Biological Products Co., Ltd. (Kangh), a Chinese company. Its license provides world-wide rights to the vaccine outside of the Chinese market. HIL-216 includes six common norovirus genotypes: GI.1, GII.2, GII.3, GII.4, GII.6 and GII.17.
Follow-Up Questions
¿Quién es el CEO de Hillevax Inc?
Dr. Robert Hershberg es el Chairman of the Board de Hillevax Inc, se unió a la empresa desde 2020.
¿Qué tal es el rendimiento del precio de la acción HLVX?
El precio actual de HLVX es de $2.09, ha decreased un 0% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Hillevax Inc?
Hillevax Inc pertenece a la industria Biotechnology y el sector es Health Care
¿Cuál es la capitalización bursátil de Hillevax Inc?
La capitalización bursátil actual de Hillevax Inc es $104.7M
¿Es Hillevax Inc una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 4 analistas han realizado calificaciones de análisis para Hillevax Inc, incluyendo 0 fuerte compra, 0 compra, 3 mantener, 1 venta, y 0 fuerte venta